Kreidezeit 31: Antisense-Technik Video

Recent Police Force News:

Antisense-Pharma

Antisense Therapy and the creation of the SOD1 protein.

Kreidezeit 40: Gel-Elektrophorese

Kreidezeit 81: Knockout Maus

Leaders from Drug Delivery Industry to Discuss Advances in Biotech, Nanotech and Targeted Delivery Technologies at Arrowhead's 3rd Annual Drug D
Arrowhead's 3rd Annual Drug Delivery Summit, scheduled to take place in San Francisco, CA on May 14th and May 15th, 2009, will be bringing together leaders from the drug delivery industry to discuss the newest and most important advances being made in the field of drug delivery.

Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
Dalton Pharma Services announces the renewal of its Chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd. Under the agreement Dalton will continue to provide chemistry services in support of Boehringer's pharmaceutical development programs.

Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead’s 4th Annual Pain Therapeutics Summit
Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics.

Arrowhead Publishers Releases New Report Analyzing the Global Cancer Therapy Market
A New report from Arrowhead Publishers entitled Cancer Therapeutics: Market Insight and R&D Pipeline Analysis provides valuable insight into the global market for cancer therapies and developmental-stage therapies.

Global Non-Small Cell Lung Cancer Therapeutics Market to Reach $13.3 Billion by 2015, According to New Report by Global Industry Analysts
GIA announces the release of a comprehensive global report on Lung Cancer Therapeutics market. World market for non-small cell lung cancer therapeutics is expected to reach $13.3 billion by 2015 fueled by rising incidence of lung cancer, improved understanding of non-small cell lung cancer, and the development of new treatments targeted at growth factor pathways.

Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhase®HL – High Loaded Solid Support for Oligonucleotide S
NittoPhase® HL Loaded up to 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and Increase Yields

Industry Experts and Global Regulators to Discuss Oligonucleotide-Based Therapeutics Issues
The Drug Information Association (DIA), in collaboration with the FDA, Oligonucleotide Therapeutics Society, Health Canada, and the American Association of Pharmaceutical Scientists, will host the 2nd Conference on Oligonucleotide-based Therapeutics (September 22 - 24; Falls Church, VA).

Global Market for Hepatitis C Virus Therapeutics to Reach $9.1 billion by 2015, According to New Report by Global Industry Analysts
The HCV therapeutic development landscape continues to inflate and currently possesses three compounds in Phase III clinical studies, several novel therapies in Phase II and Phase I pipeline, and numerous new compounds in animal-stage study and research stages. Driven by the new drug launches, the global HCV therapeutics market is forecast to reach $9.1 billion by 2015.

cordblood.asia

antisensedrugs.com
The antisense drug resource

adultstemcell.org
The adult stem cell forum

bionews.org

drugengineering.com